King's College London

Research portal

A multi-centre, cross-sectional study of the clinical and demographic factors that influence the severity of palmoplantar pustulosis: Findings from the APRICOT, PLUM and ERASPEN consortia

Research output: Contribution to journalArticle

Standard

A multi-centre, cross-sectional study of the clinical and demographic factors that influence the severity of palmoplantar pustulosis : Findings from the APRICOT, PLUM and ERASPEN consortia. / The APRICOT and PLUM study team; The ERASPEN consortium.

In: JAMA dermatology, 23.06.2020.

Research output: Contribution to journalArticle

Harvard

The APRICOT and PLUM study team & The ERASPEN consortium 2020, 'A multi-centre, cross-sectional study of the clinical and demographic factors that influence the severity of palmoplantar pustulosis: Findings from the APRICOT, PLUM and ERASPEN consortia', JAMA dermatology.

APA

The APRICOT and PLUM study team, & The ERASPEN consortium (Accepted/In press). A multi-centre, cross-sectional study of the clinical and demographic factors that influence the severity of palmoplantar pustulosis: Findings from the APRICOT, PLUM and ERASPEN consortia. JAMA dermatology.

Vancouver

The APRICOT and PLUM study team, The ERASPEN consortium. A multi-centre, cross-sectional study of the clinical and demographic factors that influence the severity of palmoplantar pustulosis: Findings from the APRICOT, PLUM and ERASPEN consortia. JAMA dermatology. 2020 Jun 23.

Author

The APRICOT and PLUM study team ; The ERASPEN consortium. / A multi-centre, cross-sectional study of the clinical and demographic factors that influence the severity of palmoplantar pustulosis : Findings from the APRICOT, PLUM and ERASPEN consortia. In: JAMA dermatology. 2020.

Bibtex Download

@article{8ba0702935564cdca6c5a349d4591d26,
title = "A multi-centre, cross-sectional study of the clinical and demographic factors that influence the severity of palmoplantar pustulosis: Findings from the APRICOT, PLUM and ERASPEN consortia",
abstract = "Importance: While palmoplantar pustulosis (PPP) can have a profound impact on quality of life, the factors underlying disease severity have not been studied.Objective: To define the factors associated with PPP severity.Design: We undertook an observational, cross-sectional study of two cohorts. A UK dataset was recruited through the APRICOT clinical trial (2016-2019) and its sister research study PLUM (2016-2020). A Northern European cohort was independently ascertained by the European Rare And Severe Psoriasis Expert Network (2013-2017). Settings: Patients were recruited in secondary or tertiary dermatology referral centres.Participants: The UK and Northern European cohort included 203 and 193 cases, respectively. All were or European descent. PPP was diagnosed by dermatologists, based on clinical examination and/or published consensus criteria. Main outcomes and measures: Demographics, comorbidities, smoking status, Palmoplantar Pustulosis Area Severity Index (PPPASI) or Physician Global Assessment (PGA). Results: Among the 203 UK patients (43 males, 160 females; median age of onset [IQR] 48 [38-59] years), the PPPASI was inversely correlated with age of onset (r=-0.18, P=0.014). Similarly, in the 159 Northern European cases that were eligible for inclusion in this analysis (25 males, 134 females ; median age of onset [IQR] 45 [34-53.3] years), the median [IQR] age of onset was lower in individuals with moderate-to-severe PGA compared to those with mild-to-clear PGA 41 [30.5-52] vs 46.5 [35-55], P=0.043). In the UK sample, the median [IQR] PPPASI was higher in females than males (9.6 [3.0-16.2] vs 4.0 [1.0-11.7], P=0.0096). Likewise, moderate-to-severe PPP was more prevalent among Northern European females compared to males 57 of 134 [43%] vs 5 of 25 [20%], P=0.026).In the UK cohort, the median PPPASI [IQR] was elevated in current smokers compared to ex- and non-smokers (10.7 [4.2-17.5] vs 7 [2.0-14.4] vs 2.2 [1-6], P=0.003). Comparable differences were observed in the Northern European dataset, as the prevalence of moderate-to-severe PPP was higher in former/current smokers compared to non-smokers (51 of 130 [39%] vs 6 of 24 [25%], P=0.14).Conclusions and relevance: PPP severity is associated with early-onset disease, female sex and smoking status. Thus, smoking cessation intervention might be beneficial. ",
keywords = "PSORIASIS, INFLAMMATORY SKIN DISEASE, Palmoplantar pustulosis, PSORIATIC ARTHRITIS",
author = "{Benzian Olsson}, Natashia and Nick Dand and Charlotte Chaloner and Zsuzsa Bata-Csorgo and Riccardo Borroni and Burden, {A. David} and Cooper, {Hywel L.} and Cornelius, {Victoria R} and Suzie Cro and Tejus Dasandi and Griffiths, {Christopher Em} and K{\"u}lli Kingo and Sulev K{\~o}ks and Helen Lachmann and Helen McAteer and Freya Meynell and Ulrich Mrowietz and Richard Parslew and Prakash Patel and Pink, {Andrew E.} and Reynolds, {Nick J.} and Adrian Tanew and Kaspar Torz and Hannes Trattner and Shyamal Wahie and Warren, {Richard B.} and Andrew Wright and {The APRICOT and PLUM study team} and {The ERASPEN consortium} and Jonathan Barker and Navarini, {Alexander A.} and Catherine Smith and Francesca Capon",
year = "2020",
month = jun,
day = "23",
language = "English",
journal = "JAMA dermatology",
issn = "2168-6068",
publisher = "American Medical Association",

}

RIS (suitable for import to EndNote) Download

TY - JOUR

T1 - A multi-centre, cross-sectional study of the clinical and demographic factors that influence the severity of palmoplantar pustulosis

T2 - Findings from the APRICOT, PLUM and ERASPEN consortia

AU - Benzian Olsson, Natashia

AU - Dand, Nick

AU - Chaloner, Charlotte

AU - Bata-Csorgo, Zsuzsa

AU - Borroni, Riccardo

AU - Burden, A. David

AU - Cooper, Hywel L.

AU - Cornelius, Victoria R

AU - Cro, Suzie

AU - Dasandi, Tejus

AU - Griffiths, Christopher Em

AU - Kingo, Külli

AU - Kõks, Sulev

AU - Lachmann, Helen

AU - McAteer, Helen

AU - Meynell, Freya

AU - Mrowietz, Ulrich

AU - Parslew, Richard

AU - Patel, Prakash

AU - Pink, Andrew E.

AU - Reynolds, Nick J.

AU - Tanew, Adrian

AU - Torz, Kaspar

AU - Trattner, Hannes

AU - Wahie, Shyamal

AU - Warren, Richard B.

AU - Wright, Andrew

AU - The APRICOT and PLUM study team

AU - The ERASPEN consortium

AU - Barker, Jonathan

AU - Navarini, Alexander A.

AU - Smith, Catherine

AU - Capon, Francesca

PY - 2020/6/23

Y1 - 2020/6/23

N2 - Importance: While palmoplantar pustulosis (PPP) can have a profound impact on quality of life, the factors underlying disease severity have not been studied.Objective: To define the factors associated with PPP severity.Design: We undertook an observational, cross-sectional study of two cohorts. A UK dataset was recruited through the APRICOT clinical trial (2016-2019) and its sister research study PLUM (2016-2020). A Northern European cohort was independently ascertained by the European Rare And Severe Psoriasis Expert Network (2013-2017). Settings: Patients were recruited in secondary or tertiary dermatology referral centres.Participants: The UK and Northern European cohort included 203 and 193 cases, respectively. All were or European descent. PPP was diagnosed by dermatologists, based on clinical examination and/or published consensus criteria. Main outcomes and measures: Demographics, comorbidities, smoking status, Palmoplantar Pustulosis Area Severity Index (PPPASI) or Physician Global Assessment (PGA). Results: Among the 203 UK patients (43 males, 160 females; median age of onset [IQR] 48 [38-59] years), the PPPASI was inversely correlated with age of onset (r=-0.18, P=0.014). Similarly, in the 159 Northern European cases that were eligible for inclusion in this analysis (25 males, 134 females ; median age of onset [IQR] 45 [34-53.3] years), the median [IQR] age of onset was lower in individuals with moderate-to-severe PGA compared to those with mild-to-clear PGA 41 [30.5-52] vs 46.5 [35-55], P=0.043). In the UK sample, the median [IQR] PPPASI was higher in females than males (9.6 [3.0-16.2] vs 4.0 [1.0-11.7], P=0.0096). Likewise, moderate-to-severe PPP was more prevalent among Northern European females compared to males 57 of 134 [43%] vs 5 of 25 [20%], P=0.026).In the UK cohort, the median PPPASI [IQR] was elevated in current smokers compared to ex- and non-smokers (10.7 [4.2-17.5] vs 7 [2.0-14.4] vs 2.2 [1-6], P=0.003). Comparable differences were observed in the Northern European dataset, as the prevalence of moderate-to-severe PPP was higher in former/current smokers compared to non-smokers (51 of 130 [39%] vs 6 of 24 [25%], P=0.14).Conclusions and relevance: PPP severity is associated with early-onset disease, female sex and smoking status. Thus, smoking cessation intervention might be beneficial.

AB - Importance: While palmoplantar pustulosis (PPP) can have a profound impact on quality of life, the factors underlying disease severity have not been studied.Objective: To define the factors associated with PPP severity.Design: We undertook an observational, cross-sectional study of two cohorts. A UK dataset was recruited through the APRICOT clinical trial (2016-2019) and its sister research study PLUM (2016-2020). A Northern European cohort was independently ascertained by the European Rare And Severe Psoriasis Expert Network (2013-2017). Settings: Patients were recruited in secondary or tertiary dermatology referral centres.Participants: The UK and Northern European cohort included 203 and 193 cases, respectively. All were or European descent. PPP was diagnosed by dermatologists, based on clinical examination and/or published consensus criteria. Main outcomes and measures: Demographics, comorbidities, smoking status, Palmoplantar Pustulosis Area Severity Index (PPPASI) or Physician Global Assessment (PGA). Results: Among the 203 UK patients (43 males, 160 females; median age of onset [IQR] 48 [38-59] years), the PPPASI was inversely correlated with age of onset (r=-0.18, P=0.014). Similarly, in the 159 Northern European cases that were eligible for inclusion in this analysis (25 males, 134 females ; median age of onset [IQR] 45 [34-53.3] years), the median [IQR] age of onset was lower in individuals with moderate-to-severe PGA compared to those with mild-to-clear PGA 41 [30.5-52] vs 46.5 [35-55], P=0.043). In the UK sample, the median [IQR] PPPASI was higher in females than males (9.6 [3.0-16.2] vs 4.0 [1.0-11.7], P=0.0096). Likewise, moderate-to-severe PPP was more prevalent among Northern European females compared to males 57 of 134 [43%] vs 5 of 25 [20%], P=0.026).In the UK cohort, the median PPPASI [IQR] was elevated in current smokers compared to ex- and non-smokers (10.7 [4.2-17.5] vs 7 [2.0-14.4] vs 2.2 [1-6], P=0.003). Comparable differences were observed in the Northern European dataset, as the prevalence of moderate-to-severe PPP was higher in former/current smokers compared to non-smokers (51 of 130 [39%] vs 6 of 24 [25%], P=0.14).Conclusions and relevance: PPP severity is associated with early-onset disease, female sex and smoking status. Thus, smoking cessation intervention might be beneficial.

KW - PSORIASIS

KW - INFLAMMATORY SKIN DISEASE

KW - Palmoplantar pustulosis

KW - PSORIATIC ARTHRITIS

M3 - Article

JO - JAMA dermatology

JF - JAMA dermatology

SN - 2168-6068

ER -

View graph of relations

© 2018 King's College London | Strand | London WC2R 2LS | England | United Kingdom | Tel +44 (0)20 7836 5454